$ZVRA
ZEVRA THERAPEUTICS, INC.

2016 Q1 Form 10-Q Financial Statement

#000156459016019302 Filed on May 13, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.740M $980.0K
YoY Change 281.63% 84.91%
% of Gross Profit
Research & Development $3.234M $2.119M
YoY Change 52.62% 104.14%
% of Gross Profit
Depreciation & Amortization $26.00K $20.00K
YoY Change 30.0% 5.26%
% of Gross Profit
Operating Expenses $6.970M $3.096M
YoY Change 125.13% 96.95%
Operating Profit -$6.970M -$3.096M
YoY Change 125.13% 96.95%
Interest Expense $1.150M $632.0K
YoY Change 81.96% 558.33%
% of Operating Profit
Other Income/Expense, Net $4.048M -$2.871M
YoY Change -241.0% 749.41%
Pretax Income -$2.922M -$5.967M
YoY Change -51.03% 212.41%
Income Tax $12.00K $7.000K
% Of Pretax Income
Net Earnings -$2.934M -$5.974M
YoY Change -50.89% 213.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20 -$2.50
Diluted Earnings Per Share -$0.20 -$2.50
COMMON SHARES
Basic Shares Outstanding 14.50M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $111.0M $10.30M
YoY Change 977.67%
Cash & Equivalents $77.33M $10.27M
Short-Term Investments $33.70M
Other Short-Term Assets $400.0K $100.0K
YoY Change 300.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $111.4M $10.30M
YoY Change 981.43%
LONG-TERM ASSETS
Property, Plant & Equipment $400.0K $400.0K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $3.400M
YoY Change -97.06%
Total Long-Term Assets $513.0K $3.800M
YoY Change -86.5%
TOTAL ASSETS
Total Short-Term Assets $111.4M $10.30M
Total Long-Term Assets $513.0K $3.800M
Total Assets $111.9M $14.10M
YoY Change 693.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.200M $4.000M
YoY Change 5.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.700M $0.00
YoY Change
Total Short-Term Liabilities $5.845M $4.000M
YoY Change 46.13%
LONG-TERM LIABILITIES
Long-Term Debt $90.10M $18.50M
YoY Change 387.03%
Other Long-Term Liabilities $11.00K $17.70M
YoY Change -99.94%
Total Long-Term Liabilities $11.00K $36.20M
YoY Change -99.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.845M $4.000M
Total Long-Term Liabilities $11.00K $36.20M
Total Liabilities $5.856M $40.30M
YoY Change -85.47%
SHAREHOLDERS EQUITY
Retained Earnings -$107.8M
YoY Change
Common Stock $96.28M $2.000K
YoY Change 4813700.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.48M -$26.10M
YoY Change
Total Liabilities & Shareholders Equity $111.9M $14.10M
YoY Change 693.89%

Cashflow Statement

Concept 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$2.934M -$5.974M
YoY Change -50.89% 213.6%
Depreciation, Depletion And Amortization $26.00K $20.00K
YoY Change 30.0% 5.26%
Cash From Operating Activities -$3.870M -$4.000M
YoY Change -3.25% 349.44%
INVESTING ACTIVITIES
Capital Expenditures $66.00K $21.00K
YoY Change 214.29% 425.0%
Acquisitions
YoY Change
Other Investing Activities -$14.67M
YoY Change
Cash From Investing Activities -$14.73M -$20.00K
YoY Change 73550.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 63.61M 4.030M
YoY Change 1478.41% -20250.0%
NET CHANGE
Cash From Operating Activities -3.870M -4.000M
Cash From Investing Activities -14.73M -20.00K
Cash From Financing Activities 63.61M 4.030M
Net Change In Cash 45.01M 10.00K
YoY Change 450000.0% -101.1%
FREE CASH FLOW
Cash From Operating Activities -$3.870M -$4.000M
Capital Expenditures $66.00K $21.00K
Free Cash Flow -$3.936M -$4.021M
YoY Change -2.11% 349.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2119000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2372000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
30000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-679000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-977000
CY2016Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
11000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3865000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
977000
CY2016Q1 kmph Deferred Offering Costs Write Off
DeferredOfferingCostsWriteOff
445000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
6970000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
3096000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6970000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3096000
CY2016Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4740000
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
442000
CY2015Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
477000
CY2016Q1 us-gaap Interest Expense
InterestExpense
1150000
CY2015Q1 us-gaap Interest Expense
InterestExpense
632000
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10278000
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1762000
CY2016Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
102000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4048000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2871000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2922000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5967000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-2934000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-5974000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.50
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14495703
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2387092
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1022000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
91000
CY2016Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
968000
CY2015Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
632000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3999000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
CY2015Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
8000
CY2016Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
24000
CY2015Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
40000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
63612000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4034000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
45015000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
14666000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-14732000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-21000
CY2016Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
82800000
CY2016Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
18621000
CY2016Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
583000
CY2016Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
8000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10255000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10269000
CY2016Q1 us-gaap Interest Paid
InterestPaid
182000
CY2015Q1 kmph Deferred Offering Costs Included In Accounts Payable And Accrued Expense
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense
442000
CY2016Q1 kmph Transfer Of Warrants To Equity Upon Exercise
TransferOfWarrantsToEquityUponExercise
82000
CY2016Q1 kmph Fixed Assets Included In Accounts Payable And Accrued Expenses
FixedAssetsIncludedInAccountsPayableAndAccruedExpenses
12000
CY2016Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
309000
CY2016Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
27479000
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
17728000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11354118
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11045601
CY2016Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
33668000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19002000
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
386000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2758000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
111387000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
54078000
CY2016Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
18000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5845000
CY2016Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
90086000
CY2015Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
11118000
CY2016Q1 kmph Derivative And Warrant Liability Noncurrent
DerivativeAndWarrantLiabilityNoncurrent
27479000
CY2015Q4 kmph Derivative And Warrant Liability Noncurrent
DerivativeAndWarrantLiabilityNoncurrent
37839000
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11000
CY2015Q4 us-gaap Liabilities
Liabilities
64711000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
96275000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
94702000
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107758000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104824000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
-11482000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-10121000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111939000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54590000
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgements about the carrying value of assets and liabilities.</p></div>
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
4200000
CY2015Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1100000
CY2016Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7.5 reverse stock split
CY2015Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.13
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2016Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12780729
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7124961
CY2016Q1 kmph Common Stock Issued During Period From Warrants Exercised
CommonStockIssuedDuringPeriodFromWarrantsExercised
7976
CY2015Q1 kmph Common Stock Issued During Period From Warrants Exercised
CommonStockIssuedDuringPeriodFromWarrantsExercised
10161
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1022000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
13333
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
5333
CY2016Q1 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
27479000
CY2016Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
33668000
CY2015Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
37839000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
19002000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
37839000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
15966000
CY2016Q1 kmph Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Exercises
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercises
82000
CY2016Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-10278000
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1762000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14498930
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14490954
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14498930
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
0
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
0
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3234000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14490954
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3736000

Files In Submission

Name View Source Status
0001564590-16-019302-index-headers.html Edgar Link pending
0001564590-16-019302-index.html Edgar Link pending
0001564590-16-019302.txt Edgar Link pending
0001564590-16-019302-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kmph-10q_20160331.htm Edgar Link pending
kmph-20160331.xml Edgar Link completed
kmph-20160331.xsd Edgar Link pending
kmph-20160331_cal.xml Edgar Link unprocessable
kmph-20160331_def.xml Edgar Link unprocessable
kmph-20160331_lab.xml Edgar Link unprocessable
kmph-20160331_pre.xml Edgar Link unprocessable
kmph-ex103_83.htm Edgar Link pending
kmph-ex104_84.htm Edgar Link pending
kmph-ex311_79.htm Edgar Link pending
kmph-ex312_80.htm Edgar Link pending
kmph-ex321_81.htm Edgar Link pending
kmph-ex322_82.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending